1. Home
  2. LILAK vs VERA Comparison

LILAK vs VERA Comparison

Compare LILAK & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Latin America Ltd. Class C

LILAK

Liberty Latin America Ltd. Class C

HOLD

Current Price

$8.47

Market Cap

1.7B

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$30.20

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LILAK
VERA
Founded
2017
2016
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
3.0B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
LILAK
VERA
Price
$8.47
$30.20
Analyst Decision
Hold
Strong Buy
Analyst Count
1
10
Target Price
$8.20
$81.30
AVG Volume (30 Days)
1.3M
1.8M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
7.55
N/A
EPS
N/A
N/A
Revenue
$4,442,200,000.00
N/A
Revenue This Year
$1.37
N/A
Revenue Next Year
N/A
$472.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.75
$21.04
52 Week High
$9.13
$56.05

Technical Indicators

Market Signals
Indicator
LILAK
VERA
Relative Strength Index (RSI) 61.73 34.87
Support Level $7.23 $30.59
Resistance Level $8.97 $31.80
Average True Range (ATR) 0.35 1.67
MACD 0.05 -0.28
Stochastic Oscillator 75.03 16.78

Price Performance

Historical Comparison
LILAK
VERA

About LILAK Liberty Latin America Ltd. Class C

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: